Expert Consensus Reaffirms Atherosclerotic Cardiovascular Disease as Leading Mortality Driver in Systemic Lupus Erythematosus
Feb 05, 2025
Research Highlights HDL2 Subfraction Association with Improved Endothelial Function in Systemic Lupus Erythematosus
Jan 22, 2024
Low-Attenuation Coronary Plaque Volume Identified as Major Predictor of Cardiovascular Events in New Journal Publication
Dec 25, 2023
PDS-2™ mentioned in Medical Device And Diagnostic Industry
Apr 19, 2021
PDS-2™ featured in FDA’s “Reflections on a Record Year for Novel Device Innovation Despite COVID-19 Challenges” report
Feb 16, 2021
PDS-2™ System Pivotal Trial Results Published in the Journal of American College of Cardiology
Dec 22, 2020
Dr. Brian Ghoshhajra Details the Significance of the PDS-2™ System in Affecting Progression of HoFH
Dec 5, 2019
HDL Therapeutics Registration Trial of PDS-2™ System in Homozygous Familial Hypercholesterolemia Selected as a 2019 Best of American Heart Association Specialty Conference Presentation
Nov 17, 2019
HDL Therapeutics Announces Positive Data From Registration Trial of PDS-2™ System in Homozygous Familial Hypercholesterolemia
May 15, 2019
Coronary Atheroma Regression from Serial Infusions of Autologous Selectively Delipidated Preβ-HDL-enriched Plasma on Coronary Atheroma in Patients With Homozygous Familial Hypercholesterolemia in the HALO-FH Trial
May 15, 2019
American Heart Association’s Vascular Discovery: From Genes to Medicine Scientific Sessions
May 15, 2019
A First in Man, Randomized, Placebo Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome
2010
Journal of The American College of Cardiology. 15:55:2727-2735. Waksman, Brewer, et al.
2010
Selective Delipidation of Plasma HDL Enhances Reverse Cholesterol Transport In Vivo
2009
Journal of Lipid Research. 50:894-907. Sacks, Brewer, et al.
2009
